In addition to the legal success, Exelixis has received an upgrade from B of A Securities. The firm has maintained a Buy rating and raised the price target from $30 to $32. This optimistic outlook ...
The secret to the company's success is Cabometyx, a cancer medicine that continues to impress. Cabometyx is the top-prescribed therapy of its type in renal cell carcinoma (kidney cancer).
Some results have been hidden because they may be inaccessible to you